SLC5A2 and Hypoglycemia: Modern therapies for the treatment of type 2 diabetes, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have consistently demonstrated efficacy in terms of reducing glycated hemoglobin (HbA1c) levels and body weight, while offering minimal risk of hypoglycemia.